Reforgene Medicine utilizes gene editing and genomic technology to develop curative therapies for genetic diseases, specifically targeting conditions like thalassemia and Usher syndrome. Their approach aims to provide lifelong cures through a single administration of gene editing treatments, addressing the significant unmet medical needs of patients suffering from these hereditary disorders.
Funding
Funding not disclosed
Founders
Product
Problem
Many genetic diseases, such as thalassemia and Usher syndrome, lack curative treatments, requiring patients to undergo lifelong management of symptoms. Current treatments often fail to address the underlying genetic cause, leading to a continued decline in health and quality of life.
Solution
Reforgene Medicine is developing potentially curative gene editing therapies for genetic diseases. Their approach involves a single administration of gene editing treatments designed to correct the underlying genetic defects responsible for conditions like thalassemia and Usher syndrome. By targeting the root cause of these diseases, Reforgene aims to provide patients with a lifelong cure, eliminating the need for ongoing treatments and improving long-term health outcomes. The company's lead programs focus on addressing significant unmet medical needs in hereditary disorders through innovative gene editing technology.
Target Audience
The primary target audience includes patients suffering from genetic diseases such as thalassemia and Usher syndrome, as well as their families and healthcare providers seeking curative treatment options.
Features
- Development of RM-001, a gene editing drug for the treatment of β-thalassemia.
- Development of RM-101, a gene editing drug for the treatment of Usher syndrome.
- Utilizes a novel CasRm gene editing system (derived from the CRISPR-Cas13 family) for efficient and safe gene editing.
- Applying for international patents for the CasRm system, covering various RNA editing applications.
- Focus on in vivo gene editing to correct genetic mutations directly within the patient's cells.
- Aims for a one-time treatment administration for lifelong therapeutic effect.